Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Sirrivastatin Was Newly Initiated (vol 83, pg 1316, 2008)

被引：0
|
作者：
Jacobson
机构：
来源：
MAYO CLINIC PROCEEDINGS | 2009年 / 84卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 12 条
  • [1] Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated
    Jacobson, Terry A.
    Wertz, Debra A.
    Hoy, Tracey
    Kuznik, Andreas
    Grochulski, Daniel
    Cziraky, Mark
    MAYO CLINIC PROCEEDINGS, 2008, 83 (12) : 1316 - 1325
  • [2] Cardiovascular event rates among newly-inititated atorvastatin and simvastatin patients with no prior history of cardiovascular disease
    Jacobson, Terry A.
    Wertz, Debra A.
    Hoy, Tracey
    Kuznik, Andreas
    Grochulski, Daniel
    Cziraky, Mark
    CIRCULATION, 2008, 117 (21) : E465 - E465
  • [3] Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: US managed care study (vol 24, pg 1987, 2008)
    Foody, J. M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (03) : 631 - 631
  • [4] CARDIOVASCULAR EVENT RATES IN STABLE CORONARY PATIENTS WITH CHRONIC KIDNEY DISEASE, INCREASED BY THE PRESENCE OF OBESITY, ARE REDUCED BY INTENSIVE LIPID LOWERING WITH ATORVASTATIN
    Deedwania, Prakash C.
    Shepherd, James
    Wilson, Daniel J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [5] COMPARISON OF CARDIOVASCULAR DISEASE EVENT RATES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS ACROSS 10 COUNTRIES - IMPLICATIONS FOR CV RISK ASSESSMENT
    Gabriel, S.
    Crowson, C.
    Matteson, E.
    Kitas, G.
    Douglas, K.
    Sandoo, A.
    Semb, A. G.
    Rollefstad, S.
    Ikdahl, E.
    van Riel, P.
    Arts, E.
    Fransen, J.
    Rantapaa-Dahlqvist, S.
    Wallberg-Jonsson, S.
    Innala, L.
    Karpouzas, G.
    Sfikakis, P.
    Zampeli, E.
    Dessein, P.
    Tsang, L.
    Gonzalez-Gay, M. A.
    Corrales, A.
    El-Gabalawy, H.
    Hitchon, C.
    Ramos, V. Pascual
    Yanez, I. Contreras
    Solomon, D.
    Liao, K.
    van de laar, M.
    Vonkeman, H.
    Meek, I.
    Husni, E.
    Overman, R.
    Colunga, I.
    Galarza, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 243 - 243
  • [6] Differences in real-world cardiovascular event rates between atorvastatin and simvastatin among new users when LDL-lowering is controlled (vol 115, pg e254, 2007)
    Willke
    CIRCULATION, 2007, 116 (07) : E305 - E305
  • [7] Pharmacogenetic Association of the NPPA T2238C Genetic Variant With Cardiovascular Disease Outcomes in Patients With Hypertension (vol 299, pg 296, 2008)
    Lynch, A., I
    Boerwinkle, E.
    Davis, B. R.
    Ford, C. E.
    Eckfeldt, J. H.
    Leiendecker-Foster, C.
    Arnett, D. K.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (10): : 1057 - 1057
  • [8] Renin Angiotensin System blockade and cardiovascular outcomes in patients with Chronic Kidney Disease and Proteinuria: A Meta-analysis (vol 155, pg 791, 2008)
    Balamuthusamy
    Jalandhara, Nishant
    AMERICAN HEART JOURNAL, 2009, 157 (03) : 501 - 501
  • [9] Left ventricular twist mechanics and its relation with aortic stiffness in chronic kidney disease patients without overt cardiovascular disease (vol 14, pg 10, 2016)
    Sulemane, Samir
    Panoulas, Vasileios F.
    Konstantinou, Klio
    Bratsas, Athanasios
    Graspa, Julia
    Tam, Frederick W.
    Brown, Edwina A.
    Nihoyannopoulos, Petros
    CARDIOVASCULAR ULTRASOUND, 2016, 14
  • [10] Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy (vol 118, pg e29, 2008)
    不详
    CIRCULATION, 2008, 118 (06) : E108 - E108
12